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Seroepidemiologic studies have shown an association of Chlamydia pneumoniae antibody with atherosclerosis. 
Compelling additional evidence has accumulated, in that the organism has been found within atherosclerotic lesions 
throughout the arterial tree by multiple methods. C. pneumoniae has also been isolated from coronary and carotid 
atheromatous plaques. Although these studies support a potential role for C. pneumoniae in atherogenesis, confirmation 
of a causal relationship requires the use of animal models and intervention studies. We have focused on the evaluation 
of mouse models to address the hypothesis that, following upper respiratory tract infection, lung macrophages are 
infected, disseminate to the aorta, and alter the onset or progression of atherogenesis. ApoE-deficient knock-out and 
C57BU6J mice were used. The apoE-deficient mouse develops atherosclerotic lesions spontaneously on a regular diet 
in a time- and age-dependent manner. This knock-out strain was developed on the background of the C57BU6J mouse, 
which only develops atherosclerosis on a high-fauhigh-cholesterol diet. To investigate whether infected macrophages 
constitute a vehicle for dissemination of C. pneumoniae in vivo, mice were inoculated intranasally or intraperitoneally. 
The organism was detected in harvested alveolar and peritoneal macrophages at all time points following intranasal 
and intraperitoneal inoculations, respectively, and in peripheral blood mononuclear cells following inoculation by both 
routes. In another experiment, alveolar and peritoneal macrophages from intranasally and intraperitoneally inoculated 
mice were adoptively transferred by intraperitoneal injection to uninfected mice. Subsequently, C. pneumoniae was 
detected in lung, spleen, abdominal lymph nodes and/or thymus of recipient mice. In control experiments, UV- 
inactivated C. pneumoniae DNA was not detected in alveolar or peritoneal macrophages beyond 5 min after inoculation 
in vivo. These cumulative results demonstrate that C. pneumoniae infects macrophages in vivo and that macrophages 
can serve as a vehicle for dissemination to other sites. 
To answer the question of whether the organism disseminates to and persists in the aorta, 8-week-old mice were infected 
intranasally. Following single or multiple inoculations in apoE-deficient mice, C. pneumoniae was detected in the lung 
and aorta for 20 weeks postinfection. In contrast, in C57BU6J mice, the organism did not persist in the aorta following 
a single intranasal inoculation, but could be detected up to 7 weeks postinfection in multiply inoculated mice. 
Significantly, in apoE-deficient mice with developed atherosclerotic lesions, the organism was found in foam cells within 
the lesions by immunocytochemical staining. These studies show that persistent C. pneumoniae infection occurs in 
atherosclerotic lesions in the aorta in the apoE-deficient knock-out mouse model. Infection of the aorta also occurred in 
C57BU6J mice but was more transient. Both models should be useful in studying the pathogenic role of C. pneumoniae 
in atherogenesis and for determining if therapy prevents dissemination of infection. 
To this end, we have evaluated the susceptibility of C. pneumoniae to roxithromycin, a new macrolide, in vitro in cell 
culture and in vivo in the apoE-deficient mouse model. In vitro results compare favorably with other new macrolides, 
quinolines, and tetracyline. Preliminary studies in the apoE model of persistent infection suggest that the organism is 
detected less frequently in the lung and aorta by PCR following treatment. These promising preliminary studies warrant 
further investigation. 
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Clilarnydia prre~ri~urziar is a hunian respiratory pathogen. 
I t  is an etiologic agent of acute respiratory disease, 
causing approximately 10%) of cases of community- 
acquired pneumonia and 5% of cases of pharyngitis, 
bronchitis, and sinusitis [ 11. Cumulative seroepidemio- 
logic studies have shown that almost everyone is 
infected at least once in their lifetime and that reinfec- 
tion is common [Z]. Antibody against C. p~eumoniae is 
rare in children under the age of- 5 years, except in 
underdeveloped and tropical countries. The antibody 
prevalence increases rapidly between the ages of 3 to 
14, reaches 50%) at the age of 20, and continues to 
increase slowly to 70-80‘% in 00-70 year-old- 
persons [ 1 J .  
The expanding clinical spectrum of C. piieurnotiiae 
infection has been extended to atherosclerosis and 
related clinical manifestations such as coronary heart 
disease, carotid artery stenosis, aortic aneurysm, 
claudication, and stroke. The first study showing an 
asrociation of this organism with atherosclerosis was 
reported by Saikku et al, who showed that patients with 
coronary artery disease were significantly more likely to 
have serologic evidence of past infection with C. 
przerrrrzoniae 12-51, These observations have been con- 
firmed by other investigators and also extended to 
carotid artery disease and cerebrovascular disease 
[6-11]. Compelling evidence for the association of C:. 
przeurnurziar with atherosclerosis has been obtained by 
the demonstration of C. pneurnoniae by PCK. immuno- 
cytochemical staining and electron microscopy in 
atherosclerotic lesions [12,13). Evidence of the organism 
has been found in coronary, carotid, aortic, femoral, 
iliac and popliteal atheromas in both early lesions and 
developed fibrolipid plaques and in abdominal 
aneurysms [I 4-26]. Finally, C. pneirvnoniae has been 
isolated from coronary and carotid atheromatous 
plaques [27,28]. 
The role of C. pnrumoniae in atherosclerosis has yet 
to be determined. Our working hypothesis is that, 
following upper respiratory tract infection, C. pizeu- 
~ o r i i a r  infects lung inacrophages, which disseminate via 
hematogeiious and/or lymphatic routes to the aorta 
and affect the onset, severity or progression of the disease 
process. Two mouse models have been developed to 
stndy this hypothesis. ApoE-deficient mice develop 
atherosclerosis on a normal diet in a time-dependent 
manner, developing lesions showing similar character- 
istics to human disease 129-311. CS7BL/6J mice, the 
background strain of apoE-deficient mice, do not 
develop atherosclerosis on a normal chow diet but will 
develop atherosclerosis on a high-fdhigh-cholesterol 
dier. This report summarizes our findings using these 
mousc models for studies on infection, dissemination, 
and interventioii. 
MATERIALS AND METHODS 
C. pneumoniae strain and inoculum preparation 
C. piieumoniae, strain AK-39 [32] ,  was used for 
inoculation of animals. The organism was grown in HL 
cells and purified by density gradient using diatrizoate 
nieglumine centrifugation (Hypaque-76; Winthrop- 
Breon Laboratories, New York, NY, USA) 1331. The 
inoculum preparations were resuspended in chlamydia 
transport media (sucrose phosphate glutaniic acid) and 
frozen a t  -70°C until use. 
For controls, UV-inactivated organisms were used 
in sonic experiments. Inactivation was done by 
exposure to UV light at a distance of 13 cni for 30 min 
at room temperature. Subsequently, organisms were 
frozen a t  -70°C. Prior to inoculation, the inoculuni 
was tested for viability by HL cell culture. No inclu- 
sions were seen by immunofiuorescence after 5 days of- 
incubation. 
Inoculation of mice 
Sixty-eight male honiozygous apoE-deficient mice and 
122 male and female C57BL/6J mice, aged 6-7 weeks, 
were obtained from the Jackson Laboratories (Bar 
Harbor, Maine, USA). As previously described, mice 
were inoculated intranasally with 3-5 x 10’ inclusioii- 
forming units (IFUs) with a total volume of 0.03- 
0.05 mL suspended in SPG medium or inoculated with 
SPG rncdjuni alone at  8 weeks of age J33J. Multiply 
inoculated apoE-deficient mice were inoculated at 8. 
10 and 12 weeks of age. Multiply inoculated C57BL/6J 
mice were inoculated at 8, 9 and 10 weeks of age. 
Intraperitoneauy inoculated mice received 5 X 10’ IFU 
per animal in a total volume of 0.5 id SPG medium. 
AU aninials receiving inactivated organisms were given 
identical doses of inoculum. Control mice were sham- 
iiioculated with 0.03 mL of sterile SPG medium. 
Tissue collection 
Mice were heavily sedated, and hepaririized whole 
blood cvas collected by exsanguination from the femoral 
arteries. The chest and abdomen were opened and the 
heart and aorta were pafused with phosphate-buEered 
saline (PBS). Lung, spleen, heart and ascending arid 
abdominal aorta were removed with a separate set of 
sterile instrunlents, placed in Yterik glass vials and 
immediately placed on ice. Tissues were later frozen at 
-70°C. 
Neparinized whole blood was diluted with a11 
equal voluiiie of PBS and separated by FicoU-Paque 
Plus (Pharmacia, Uppsala, Sweden) by centrifugation at 
4004~ for 30 niin a t  20°C. The b u 6  coat was \ v d ~ r d  
twice with PBS and resuspended in 2 niL ofDulbecco’s 
minimum essential medium (DMEM). Plasma. was 
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aspirated and filtered through a 0.8-pm filter before 
culture. 
Alveolar and peritoneal macrophages and peripheral 
blood were collected at 3, 5 and 7 days postinoculation 
from intranasally and intraperitoneally inoculated 
CS6BL/6J mice. Peritoneal macrophages were col- 
lected by washing the peritoneal cavity twice with 
cold Hanks’ balanced salt solution (HBSS), pH 7.2, 
containing 0.2% bovine serum albumin. Alveolar 
macrophages were collected by removing the lungs to 
a sterile Petri dish and lavaging through the trachea 
with cold HBSS. Macrophages were washed twice with 
cold PBS by centrifugation at  1000 rev/min for 10 min 
before analysis. To immediately fix macrophages at 
specific time points, cells were collected by the 
methods described above with the use of cold HBSS 
containing 0.02% phosphate-buffered formalin. 
Tissue preparation and DNA extraction 
Tissue samples were thawed and homogenized with a 
sterile pestle and mortar in 1 .O-2.0 mL of SPG medium 
to make a 10% (w/v) suspension. Tissue homogenates 
were centrifuged at SO0g for 5 min at 4°C to sediment 
tissue debris and the supernatant was aspirated for 
inoculation of cultures. Tissue pellets were resuspended 
in 1.0 mL of lysis buffer (10 mM Tris-C1, pH 8.0, 
100 mM EDTA, 0.5% sodium dodecylsulfate (SDS)), 
and 200 pg/ml proteinase K (Amresco, Solon, O H ,  
USA) was added to each sample. Samples were 
incubated overnight at 50°C and extracted with 
hexadecyltrimethyl ammonium bromide (CTAB) 
according to standard methods [34]. Lysates were 
extracted twice with phenol/chloroform/isoamyl 
alcohol (24:24: 1) and once with chloroform/isoamyl 
alcohol (24:l). DNA was precipitated with 0.7 volumes 
of 100% isopropanol at room temperature, and this was 
followed by washing with ice-cold 70% ethanol. DNA 
pellets were air-dried and resuspended in 50-100 pL of 
10 mM Tris-C1, pH 8.0, 1 mM EDTA. An extraction 
control of lysis buffer alone was included with each set 
of tissue extractions to detect cross-contamination of 
samples during the extraction process. Tissue homo- 
genization, DNA extractions and PCR amplification 
were performed in separate rooms equipped with 
germicidal lighting. 
Isolation and infectivity assay 
Human line (HL) cell monolayers in shell vials were 
inoculated with 100 pL of 10% tissue homogenate. 
Cultures were passed once, 4 days after inoculation. 
Inclusions were detected by direct fluorescent antibody 
(DFA) stain using a Chlamydia genus-specific 
monoclonal antibody (CF-2) conjugated to fluorescein 
isothiocyanate (FITC) [35]. The infectious titer was 
assayed by titration of tissue homogenates in HL cells 
and expressed as loglo IFUs per gram of lung tissue. 
Direct plating 
Alveolar and peritoneal macrophages were washed 
twice in 10 mL ofDh4EM containing 1% non-essential 
amino acids (Gibco BRL, Grand Island, NY, USA), 
2 mM glutamine and 100 pg each of vancomycin and 
streptomycin. Macrophages were counted with a 
hemocytometer following staining with 0.4% trypan 
blue dye (Sigma, St Louis, MO, USA). Based on 
morphology, approximately 70-90% of the cells 
collected were macrophages. Approximately half of the 
collected cells were directly plated and the remainder 
were frozen at -70°C for culture and PCR. 
Macrophages were plated in 24-well microtiter plates 
containing 12-mm glass coverslips at a concentration of 
2-5 X lo5 cells per well in a total volume of 1 mL of 
DMEM for up to three coverslips per sample. Cells 
were incubated at  37OC in 5% C02 overnight. Cover- 
slips were fixed with acetone and stained with FITC- 
conjugated Chlamydia genus-specific (CF-2) mono- 
clonal antibody for detection of chlamydial inclusions 
[351. 
Polymerase chain reaction 
DNA samples were amplified using C .  pneumoniae- 
specific primers HL-1 and HR-1 [36]. The amplific- 
ation product, an expected 437-bp C. pneumoniae- 
specific DNA sequence, was analyzed by gel electro- 
phoresis through a 1.5% agarose gel according to 
standard methods and transferred by Southern blot to 
a nylon membrane (Qiagen, Chatsworth, CA, USA). 
The product was confirmed by hybridization to a 
digoxigenin-dUTP-labeled probe consisting of a 474- 
bp PstI fragment which spanned the target sequence 
[36]. DNA probes were labeled using the Genius DNA 
labeling and detection kit (Boehringer Mannheim 
Biochemical, Indianapolis, IN, USA). Hybridized 
amplification products were detected by immuno- 
chemiluminescence with the use of Lumiphos 530 
(Boehringer Mannheim Biochemical, Indianapolis, IN, 
USA) according to the manufacturer’s instructions, 
followed by autoradiography. Controls for each 
amplification consisted of serial dilutions of purified C .  
pneumoniae DNA as positive controls and sterile water 
in place of sample DNA as a negative control. Positive 
and negative controls were amplified, analyzed and 
confirmed concurrently with each set of samples. 
Histopathology and immunocytochemistry 
Abdominal and ascending aorta were fixed in situ prior 
to removal by perfusion with 10 mL of PBS followed 
by 10-1 5 mL of 10% phosphate-buffered formalin 
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(Fisher Scientific, Pittsburgh, PA, USA) injected 
through the left ventricle of the heart. Lungs were 
perfused through the trachea with 10% formalin prior 
to removal. The base of the heart was collected and 
sectioned at the level of the coronary sinus. Ascending 
aorta was sampled from the junction of the aorta with 
the heart at the end of the aortic sinus through the 
aortic arch and thoracic aorta. Abdominal aorta was 
sampled from the mesenteric artery branch through the 
iliac bifurcation. Aorta from singly inoculated and 
sham-inoculated animals was cut into 2-3-mm pieces, 
embedded in paraffin, and then cross-sectioned for 
staining. Aorta from niultiply inoculated animals was 
cut into 6-8-mm pieces, embedded in paraffin and 
sectioned longitudinally. Tissues for histopathology 
were stained with heniatoxylin and eosin. 
For detection of chlamydial antigens, tissue 
sections were reacted with a Chlamydia genus-specific 
mouse monoclonal antibody (CF-2). Lung sections 
were stained by the direct avidin-biotin-peroxidase 
method using CF-2 conjugated to biotin at 1:250 
dilution as previously described [23]. Aorta sections 
were stained by the indirect method with CF-2 at 
1:1000 dilution using the HistoMouse Kit (Zymed 
Laboratories, San Francisco, CA, USA). Tissue sections 
were counter-stained with either methyl green or 
hematoxylin. Duplicate tissue sections and tissues from 
sham-inoculated mice were reacted with CF-2 and 
normal mouse ascitic fluid as negative controls. C. 
pneumoniae infected HL cell pellets were formalin fixed, 
embedded in paraffin and sectioned for positive 
controls. 
Adoptive transfer 
Alveolar macrophages were collected from 10 donor 
mice 3 days after intranasal inoculation. Peritoneal 
macrophages were collected from 10 donor mice 7 days 
afier intraperitoneal inoculation [37]. Aliquots of 5 X 10' 
cells were analyzed for the presence of C. pneumoniae 
organisms by direct plating, culture and PCR.  
Approximately 2 X 10' cells, either alveolar or 
peritoneal macrophages, were transferred by intra- 
peritoneal injection to four recipient mice. Three days 
after transfer, tissues were removed from all recipient 
mice and tested for the presence of C. pneumoniae by 
isolation and PCR.  
Roxithromycin treatment 
In vitro susceptibility of C. pneurnoniae to roxithro- 
mycin was tested in cell cultures as described previously 
[38]. The antibiotic was tested at  serial two-fold 
dilutions. Total inhibition of inclusion formation as 
determined by DFA was used as the endpoint. The 
MIC was defined as the end point for the first passage 
containing roxithromycin. The MBC was defined as 
the endpoint for the second pamge containing no 
roxithromycin. 
ApoE-deficient mice were intranasally inoculated 
at 8, 10 and 12 weeks of age. Four weeks after the final 
inoculation, mice were treated daily for 7 days with 
either roxithromycin (50 mg/kg) or 0.5% methyl- 
cellulose delivered by gastric lavage. 
RESULTS 
C. pneumoniae infection of mononuclear cells 
To determine if macrophages were infected in vivo, 
C57BL/6J mice were inoculated intranasally or intra- 
peritoneally and alveolar and peritoneal macrophages, 
respectively, were harvested. The frequency of- detec- 
tion of C. pneumoniae in macrophages and peripheral 
blood is shown in Table 1. Staining of macrophages 
with fluorescein-labeled Chlamydia genus-specific 
antibody 24 h after plating to glass coverslips detected 
the presence of chlamydial antigen, as part of either a 
developing viable inclusion or partially degraded non- 
viable organisms. Growth and detection of chlamydial 
inclusions in HL cell culture showed the presence of 
viable organisms. Productive infection was shown by 
passage of infectious particles from the initial macro- 
phage cell monolayer to freshly grown HL cells. 
At various time points, C. pnei-rmoniae was detected 
by direct plating, isolation and P C R  in alveolar 
macrophages of all intranasally inoculated mice and in 
peritoneal macrophages of all intraperitoneally inocul- 
ated mice [37]. C. pneumoniae was detected in peripheral 
blood mononuclear cells (PBMCs), but not in plasma 
in both intranasally and intraperitoneally inoculated 
animals. Alveolar macrophages from intraperitoneally 
inoculated animals and peritoneal macrophages from 
intranasally inoculated animals were negative by 
isolation and PCR at all time points. 
In C57BL/6J mice inoculated intranasally with 
UV-inactivated organisms, C .  pneumoniae DNA was 
detected by P C R  in the alveolar macrophages of one 
of two animals 5 min after inoculation. All other time 
points were negative. In C57BL/6J mice inoculated 
intraperitoneally with UV-inactivated organisms, C. 
pneirmoniae DNA was not detected by PCR a t  any time 
point up to 72 h after inoculation. UV-inactivated 
inoculum alone incubated in vitro at  37°C was positive 
by P C R  for C. pneumoniae DNA at all time points. 
Adoptive transfer 
Results of the adoptive transfer of infected niacro- 
phages to uninfected mice are shown in Table 2. The 
presence of C. pneumoniae organisms was confirmed by 
direct plating, culture and P C R  in alveolar macro- 
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Table 1 
nlice inoculated by intranasal and intraperitoneal routes. 
Frequency of C. pneumoniae in alveolar and peritoneal macrophages and peripheral blood mononuclear cells in 
Days after inoculation (“3 mice positive)” 
3 5 7 
IN IP IN IP IN IP 
Alveolar macrophages 
Direct 
Isolation 
PCR 
Direct 
Isolation 
I’CR 
PBMC 
Isolation 
PCR 
Isolation 
PCR 
Peritoneal macrophages 
Plasma 
100 
100 
100 
0 
0 
0 
50 
50 
0 
0 
0 
0 
0 
100 
100 
100 
100 
100 
0 
0 
100 
75 
100 
25 
0 
0 
0 
50 
0 
0 
0 
0 
0 
100 
75 
75 
0 
50 
0 
0 
75 
50 
75 
0 
0 
0 
50 
50 
0 
0 
0 
0 
0 
100 
75 
75 
0 
0 
0 
0 
Four mice were tested at each time point. 
IN, intranasal inoculation; IP, intraperitoneal inoculation; PBMC, peripheral blood mononuclear cells. 
Table 2 
tissues of C57BL/6J mice 3 days after intraperitoneal 
transfer of macrophages from mice infected intranasally, or 
intraperitoneally 
Detection of C. pneumoniae DNA by PCR in 
% mice positive (N=8)” 
Intranasal Intraperitoneal 
route, route, 
Tissues of alveolar peritoneal 
recipient mice niacrophagesb macrophages‘ 
Lung 25 75 
Thymus 0 75 
Spleen 75 100 
Abdominal lymph nodesd 100 75 
’Alveolar macrophages were transferred to four mice; peritoneal 
niacrophages were transferred to four mice. 
hAlveolar macrophages from intranasally infected donor mice were 
collected 3 days after inoculation. 
‘Peritoneal macrophages from intraperitoneally infected donor 
mice were collected 7 days after inoculation. 
dAbdominal lymph nodes include the superior mesenteric, renal 
and para-aortic nodes. 
phages transferred from intranasally inoculated mice 
and in peritoneal macrophages transferred from 
intraperitoneally inoculated mice. In mice receiving 
alveolar macrophages from intranasally inoculated 
donor mice, C. pneumoniae DNA was detected in lung, 
spleen and abdominal lymph nodes, but not thymus 
[37]. In mice receiving peritoneal macrophages from 
intraperitoneally inoculated donor mice, C. pneumoniae 
DNA was detected in all tissues tested. All tissues were 
negative by isolation. 
Susceptibility of apoE-deficient and C57BY6.l mice to 
C. pneumoniae 
Following a single inoculation of apoE-deficient mice, 
lung histopathology was characterized by moderate to 
severe pneumonitis with an initial polymorphonuclear 
cell infiltrate, followed by predominantly mononuclear 
cells at 2 weeks after inoculation. Lung lesions resolved 
by 6 weeks afier inoculation. C. pneumoniae was isolated 
from several tissue sites, including lung, spleen and 
aorta, during the first week of infection (Table 3 ) .  
Organisms were isolated from lung tissue at 2 and 4 
weeks and from aorta at 4 weeks after inoculation. No 
other tissues were positive by isolation at any other time 
points. Lung and aorta were intermittently positive for 
C. pneurnoniae DNA by PCR for 20 weeks after 
inoculation. When detected, the percentage of animals 
whose aorta (either ascending or abdominal) was 
positive for C. pneumoniae ranged from 33% to 100%. 
Immunocytochemical staining of lung sections in singly 
inoculated apoE-deficient mice was positive for 
chlamydial antigen at 1, 2 and 8 weeks after inocu- 
lation, but negative at all later time points [33] .  Up to 
2 weeks after inoculation, chlamydial antigen was 
distributed multifocally throughout the lung inter- 
stitium and peribronchiolar and alveolar mononuclear 
cells. At 8 weeks after inoculation, chlamydial antigen 
was found in focal interstitial cells. Aortic tissue from 
singly inoculated apoE-deficient mice was positive for 
chlamydial antigen at 16 and 20 weeks afier inocul- 
ation. Immunocytochemistry of the aorta at other time 
points was difficult to interpret because of non-specific 
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reaction of the monoclonal antibody CF-2 with 
smooth muscle cells in the tunica intima of the aorta 
and nerve cells of the surrounding adventitia. 
Subsequent retesting was not possible because of lack 
of sufficient tissue. 
In multiply inoculated apoE-deficient mice, 
moderate to severe pneumonitis with occasional inter- 
stitial mononuclear cell aggregates developed at 2 and 
4 weeks after final inoculation. Pneumonitis gradually 
decreased from 6 to 12 weeks and resolved by 16 weeks 
after inoculation. C. przeuvnoniue was isolated from lung 
and aorta (either ascending or abdominal) at 2 weeks 
after inoculation (Table 4). Lung and aorta were 
consistently positive for C. pneumoniue DNA for up to 
20 weeks after inoculation. The percentage of mice 
whose aorta was positive ranged from 50% to 100%. 
Tissues from apoE-deficient control nllce sham- 
inoculated once or three times were negative for C. 
pneurnoniae by P C R  at all time points. Immunocyto- 
chemical (ICC) staining revealed that chlamydial 
antigen was distributed multifocally throughout the 
lung interstitium and peribronchially from 2-1 0 weeks 
postinoculation. Lung tissue remained focally positive 
for chlamydial antigen for up to 20 weeks post- 
inoculation, the last time point analyzed. Aortic tissue 
was positive by ICC at 12 and 16 weeks after inocu- 
lation. Results from aortic tissue at 20 weeks after 
inoculation could not be interpreted because of cross- 
reaction of the genus-specific monoclonal antibody 
CF-2 with regions in these more advanced athero- 
sclerotic lesions which were necrotic and highly 
inflammatory [33]. Chlamydia1 antigen was present 
Table 3 
of age 
Detection of C. pneurnouiae in tissues of apoE-deficient mice following a single intranasal inoculation at 8 weeks 
% positive mice (N=31)3 
Timr after Lung Spleen Aorta 
inoculation Age 
(wreks) (weeks) Isolation P C K  Isolation PCK Irolation P C K  
1 
2 
4 
6 
8 
11) 
12 
16 
20 
9 
10 
12 
14 
16 
18 
20 
24 
28 
100 
100 
33 
0 
0 
0 
0 
0 
0 
100 
66 
66 
33 
75 
0 
25 
0 
75 
100 
0 
1) 
0 
0 
0 
I J  
0 
0 
100 
0 
33 
33 
0 
0 
1) 
0 
0 
6 6 100 
0 0 
33 33 
33 33 
0 75 
0 33 
0 0 
1) 0 
!) 5 0 
Total 23 48 10 16 1 0 35 
'X=cumulative number of m c e  tested; three or four mice were tested at each time point. 
Table 4 
weeks of age 
Detection of C. pnetrmoniae in tissues of apoE-deficient mice after multiple intranasal inoculations at 8, 10 and 12 
9'0 positive mice (A=  18)" 
Time after Lung Spleen Heart Aorta 
inoculation Age 
(weeks) (weeks) Isolation PCR Isolation PCK Isolation PCK Isolation PCli 
2 10 100 100 il 0 
4 12 0 100 0 0 
6 14 0 100 0 5 0 
1 0 18 0 33 0 0 
12 20 0 66 0 33 
16 24 0 33 0 66 
20 28 0 100 0 33 
0 100 50 100 
0 0 0 5 0 
n 50 0 50 
0 33 (1 66 
0 33 0 66 
3 3 0 66 
0 0 0 100 
Total 11 72 0 28 Cl 28 6 72 
'.\-=total number of m c e  tested, two or three mice were tested at each time point 
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within atherosclerotic plaques and appeared to be 
confined to foam cells in both atheromas and the 
subendothelium. 
In C57BL/6J mice receiving a single inoculation, 
C. pneumoniae was isolated from lung tissue up to 14 
days and detected by P C R  until 28 days after 
inoculation, the final time point tested (Table 5). Aorta 
(either ascending or abdominal) was positive by P C R  
for C. pneumoniae in 21% of animals for up to 5 days, 
decreasing to 8% at 14 days after inoculation. C. 
pneumoniae was isolated from the ascending aorta of one 
animal at  3 days after inoculation. Heart tissue was 
negative by culture and P C R  at all time points. 
In multiply inoculated C57BL/6J mice, C. 
pneumoniae was detected by P C R  in lung and ascending 
aorta for up to 35 days after inoculation (Table 6). 
Ascending aorta was positive in 80% of animals at 7 days, 
60% at 21 days and 40% at 28 and 35 days after the last 
inoculation. Heart tissue was negative at all time points. 
Susceptibility of C. pneumoniae to roxithromycin 
In vitro testing showed that roxithromycin was 
effective against C. pneumoniae isolates, yielding MICs 
of 0.0395-0.0785mg/L and MBCs of 0.0785- 
0.156 mg/L. 
Preliminary results in the mouse model suggest that 
a 7-day regimen of roxithromycin reduces the level of 
C. pneumoniae in the lung and coronary sinus of apoE- 
deficient mice at 6 and 14 weeks after treatment (Table 
7). Although the antibiotic does not clear C. 
pneumoniae from the aorta, the percentage of animals 
infected in the aorta was lower for roxithromycin- 
treated animals than for placebo-treated animals at 14 
weeks postinfection. Future studies will investigate 
whether a longer treatment regimen of 14 days is more 
effective in eradication of chronic C. pneumoniae 
infection of the aorta. 
Table 5 Detection of C. pneumoniae in tissues of C57BL/6J mice after a single intranasal inoculation at 8 weeks of age. 
% positive mice 
Time after Lung Heart Aorta 
inoculation 
(days) Isolation PCR Isolation PCR Isolation PCR 
3 
5 
7 
14 
21 
28 
100a 
100 
86 
42 
0 
0 
100 
100 
100 
83 
82 
89 
0 
0 
0 
ND 
ND 
ND 
7 
0 
0 
ND 
ND 
ND 
21 
21 
7" 
8 
0 
0 
Total 61 93 0 0 2 9 
Nb 74 74 36 74 42 74 
aAscending and abdominal aorta &om the same animal were positive. 
bCumulative number of mice; 9-14 mice were tested at each time point. 
ND. not done. 
Table 6 
tissues of C57BL/6J mice after multiple intranasal inoculations 
at 8, 9 and 10 weeks of age 
Detection of C. pneumoniae DNA by PCR in Table 7 
C. pneumoniae infection 
Efficacy of roxithromycin" in chronic 
% positive miceb 
% positive mice (N=20)" 
Time after 
inoculation Ascending Abdominal 
(days) Ling Heart aorta aorta 
Age 
(weeks) 
Coronary 
Lung sinus Aorta 
14 (pretreatment) 40 0 30 
20 (6 weeks post-treatment) 
Roxithromycin 0 0 40 
MethylceUulose 10 11 33 
Roxithromycin 11 0 20 
Methylcellulose 33 25 50 
28 (14 weeks post-treatment) 
"50 mg/kg per 0 s  once a day for 7 days. 
bFive to ten mice were tested at each time point. 
7 100 0 60 0 
21 180 0 40 0 
28 0 0 40 0 
35 40 0 20 0 
Total 55 0 40 0 
"Cumulahve number of m c e  tested; two or three mce  were tested 
at each time point. 
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DISCUSSION 
In order to address the role of C. pneumoniae infection 
in atherosclerosis, animal models that are both suscept- 
ible to C. pneumoniae infection and have well-defined 
mechariisms of atherosclerosis have been investigated. 
Such models provide the opportunity to address the 
question of whether C. pneumoniae plays a role in the 
onset, severity or progression of the disease process. We 
have shown that two mouse models of atherosclerosis, 
C57BL/6J and apoE-deficient mice, are also suscept- 
ible to C. pneumoriiae infection and can be used to study 
C. pneumoniae pathogenesis. 
By use of the C57BL/6J mouse model, our studies 
have demonstrated that C. pneumoniae survives and 
replicates within both alveolar and peritoneal 
macrophages in vivo. Mouse models have also been 
used to demonstrate that macrophages disseminate to 
other tissue sites, including the aorta, following 
respiratory infection. Specifically, in the C57BL/6J 
mouse, C. pneirmoniae-infected macrophages could 
disseminate from the peritoneal cavity to other tissue 
sites, and infection could be transferred between 
animals by infected macrophages. In the apoE-deficient 
mouse, C. pneumoriiae disseminated to the spleen, aorta 
and heart following intranasal inoculation. Most 
importantly, C. pneumoniae disseminates to and persists 
in the aorta within developing lesions for long time 
periods after respiratory tract infection. These latter 
findings validate the usefulness of the apoE-deficient 
model for determining whether persistent infection of 
the aorta enhances disease progressiori. Alternatively, 
the finding that multiple inoculations of the C57BL/6 
mouse resulted in chronic C. pneurnoniae infection of 
the aorta provides the opportunity to determine 
whether C. pneuinoniae, in the absence of atherogenic 
nutritional factors, can initiate the disease process. 
Interestingly, infection of New Zealand white rabbits 
with C. pneumoniae resulted in the accumulation of 
foam cells and proliferation of smooth muscle cells 
within the aorta [39]. Additionally, the C57BL/6J 
mouse model can be used to determine whether an 
atherogenic diet will contribute to the induction of 
atherosclerosis by C. pneumoniae. 
Another use of the mouse niodels of C. pneumoniae 
infection is to determine whether intervention is 
effective in eradication of persistent infection in the 
lung and aorta. It  is known that chlamydia1 infections 
can persist following antibiotic therapy and that 
prolonged antibiotic therapy is recommended for C. 
pneumoniae infections. Previously, we have investigated 
both in vitro and in vivo susceptibility of C. pueumoniae 
to various antibiotics, including tetracyline and 
erythromycin (401. In this study, we have shown that 
C. pneumoniae i s  equally susceptible to roxithromycin. 
The ability of this macrolide to be tolerated more 
readily and to be effective in fewer doses than erythro- 
mycin suggests that further clinical testing should be 
done. Additionally, preliminary results show that 
roxithromycin decreases the percentage of tissues that 
are PCR positive (including the aorta) in the apoE 
mouse model of C. pneumoniae infection. In previous 
studies. the effects that azithromycin and tetracycline 
treatment had on the course of infection and persis- 
tence in mouse models were similarly determined by 
detection of organisms in lungs by isolation and PCR, 
and assessment of lung pathology. Based on the inability 
to culture the organism following treatment, infection 
was assumed to be cleared. However, C. pneumoniae 
DNA could still be detected in 77% (infecting dose of 
1.3 X 10’ IFU) of culture-negative lungs by PCR [40]. 
The findings of chlamydia1 DNA in treated versus 
untreated mice raises the question as to whether the 
organism persists in some cases following treatment. 
The finding that infection in PCR-positive, culture- 
negative mouse lungs could be reactivated via immuno- 
suppression by cortisone [41J strorigly suggests that 
PCR positivity in the absence of culture reflects the 
presence of viable organisms. This supposition is 
further supported by the findings in vjvo that alveolar 
macrophages from mice infected with C. pneurnoniae 
were positive for 7 days postinfection, while macro- 
phages isolated from mice infected with UV-inactivated 
C. piienmoniae were PCK positive only immediately 
afier intranasal inoculation. Nevertheless, the results of 
the preliminary studies with roxitliromycin are en- 
couraging because long-term persistence of DNA in 
the lung, coronary sinus and aorta was decreased. 
In conclusion, these studies have shown that follow- 
ing upper respiratory tract infection, lung macrophages 
are infected and an acute cell-associated bacteremia 
occurs. Moreover, macrophages appear to serve as 3 
vehicle for dissemination of infection via hemato- 
genous and/or lymphatic routes. The demonstration of 
chronic, persistent infection within atherosclerotic 
lesions in foam cells within the aorta in the apoE- 
deficient mouse is analogous to the finding of C. 
pneumoniae within atheromatous human tissue. These 
models will be invaluable in determining whether C. 
pneumoniae plays a role in atherogenesis and addressing 
treatment modalities that are effective against chronic 
infection. 
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